|
Canada-0-HYPNOTHERAPY 公司名录
|
公司新闻:
- Symptom reduction and suicide risk in patients treated with placebo in . . .
We assessed suicides, suicide attempts, and depressive symptom reduction in studies of 7 new antidepressants using the Food and Drug Administration database Among 19,639 participating patients, 34 committed suicide (0 8% per year), and 130 attempted suicide (2 9% per year)
- (PDF) Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk . . .
We assessed suicides, suicide attempts, and depressive symptom reduction in studies of 7 new antidepressants using the Food and Drug Administration database Among 19,639 participating
- Suicide Rates in Clinical Trials of SSRIs, Other Antidepressants, and . . .
Khan A, Khan SR, Leventhal RM, Brown WA: Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database
- Antidepressants versus placebo in major depression: an overview
If the trial included two antidepressant treatments and one placebo arm (33% placebo exposure risk), the magnitude of symptom reduction with the antidepressants was 57 7%, while that with placebo was 44 6%
- A. Khan, H. A. Warner and W. A. Brown, “Symptom Reduction and Suicide . . .
A Khan, H A Warner and W A Brown, “Symptom Reduction and Suicide Risk in Patients Treated with Placebo in Antidepressant Clinical Trials,” Archives of General Psychiatry, Vol 57, No 4, 2000, pp 311-328 doi:10 1001 archpsyc 57 4 311 has been cited by the following article:
- Symptom Reduction and Suicide Risk in Patients Treated With Placebo in . . .
Symptom reduction was 40 7% with investigational drugs (n=4510), 41 7% with active comparators (n=1416), and 30 9% with placebo (n=2805) These data may help inform discussions about the use of placebo in antidepressant clinical trials
- Symptom reduction and suicide risk in patients treated with placebo in . . .
We assessed suicide risk and symptom reduction among placebo-treated patients participating in antidepressant clinical trials for two recently approved antidepressants, venlafaxine ER and citalopram, which were unavailable during our previous study
- Decreased suicide rates in recent antidepressant clinical trials
Deaths by suicide and suicide attempts have decreased significantly in antidepressant clinical trials following 2000 compared to the decade before 2000 Basic demographic features of the patients have remained consistent and medication treatment effects on suicidality were not apparent
- Antidepressants versus placebo in major depression: an overview - Khan . . .
If the trial included two antidepressant treatments and one placebo arm (33% placebo exposure risk), the magnitude of symptom reduction with the antidepressants was 57 7%, while that with placebo was 44 6%
- Symptom Reduction and Suicide Risk Among Patients Treated With Placebo . . .
OBJECTIVE: The assumption that psychotic patients assigned to placebo in clinical trials of antipsychotics are exposed to substantial morbidity and mortality is not based on data about what actuall
|
|